ATE334983T1 - Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit - Google Patents

Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit

Info

Publication number
ATE334983T1
ATE334983T1 AT03762050T AT03762050T ATE334983T1 AT E334983 T1 ATE334983 T1 AT E334983T1 AT 03762050 T AT03762050 T AT 03762050T AT 03762050 T AT03762050 T AT 03762050T AT E334983 T1 ATE334983 T1 AT E334983T1
Authority
AT
Austria
Prior art keywords
spiro
obesity
treatment
hormone receptor
substituted piperidine
Prior art date
Application number
AT03762050T
Other languages
English (en)
Inventor
Duane A Burnett
Wen-Lian Wu
Thavalakulam K Sasikumar
Martin S Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE334983T1 publication Critical patent/ATE334983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03762050T 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit ATE334983T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27

Publications (1)

Publication Number Publication Date
ATE334983T1 true ATE334983T1 (de) 2006-08-15

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762050T ATE334983T1 (de) 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit

Country Status (14)

Country Link
US (1) US7109207B2 (de)
EP (1) EP1532147B1 (de)
JP (1) JP4522853B2 (de)
CN (1) CN100374440C (de)
AR (1) AR040344A1 (de)
AT (1) ATE334983T1 (de)
AU (1) AU2003258957A1 (de)
CA (1) CA2490531C (de)
DE (1) DE60307289T2 (de)
ES (1) ES2266861T3 (de)
MX (1) MXPA05000185A (de)
PE (1) PE20040749A1 (de)
TW (1) TW200401777A (de)
WO (1) WO2004002987A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1595867A4 (de) 2003-02-10 2008-05-21 Banyu Pharma Co Ltd Piperidinderivate als wirkstoff enthaltende antagonisten am rezeptor des melaninkonzentrierenden hormons
DE602004013427T2 (de) * 2003-02-28 2009-06-04 Schering Corp. Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
US7354925B2 (en) 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006104136A1 (ja) * 2005-03-29 2006-10-05 Banyu Pharmaceutical Co., Ltd. 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
US9090084B2 (en) 2010-05-21 2015-07-28 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1299362A4 (de) * 2000-07-05 2004-11-03 Synaptic Pharma Corp Selektive rezeptorantagonisten des melaninkonzentrierenden hormons-1 (mch1) und ihre anwendung

Also Published As

Publication number Publication date
CA2490531C (en) 2011-03-22
CN1665812A (zh) 2005-09-07
US7109207B2 (en) 2006-09-19
TW200401777A (en) 2004-02-01
ES2266861T3 (es) 2007-03-01
CA2490531A1 (en) 2004-01-08
JP2005535641A (ja) 2005-11-24
AR040344A1 (es) 2005-03-30
HK1071567A1 (en) 2005-07-22
EP1532147B1 (de) 2006-08-02
EP1532147A1 (de) 2005-05-25
DE60307289T2 (de) 2007-10-18
DE60307289D1 (de) 2006-09-14
MXPA05000185A (es) 2005-04-08
PE20040749A1 (es) 2004-10-23
JP4522853B2 (ja) 2010-08-11
AU2003258957A1 (en) 2004-01-19
WO2004002987A1 (en) 2004-01-08
US20040024002A1 (en) 2004-02-05
CN100374440C (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
ATE334983T1 (de) Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit
DE60010722D1 (de) Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit
DE60130675D1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
ATE420083T1 (de) Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung
AU2003243497A8 (en) Antagonists of melanin concentrating hormone receptor
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
ATE474577T1 (de) Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
DE60312999D1 (de) Vorrichtung zum anbringen von nähten
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE602007006019D1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
MX2007004306A (es) Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados.
DE60302913D1 (de) Erweiterung des Befehlssatzes zum software-initiierten Vorausladen
FI20030469A0 (fi) Kaulakannake kannettavaa laitetta varten
DE60238709D1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
ATE393766T1 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
ATE512959T1 (de) 2-substituierte benzimidazolpiperidinanaloga als selektive antagonisten des auf das melanin- konzentrierende hormon wirkenden rezeptors zur behandlung von obesitas und verwandten erkrankungen
DE50301116D1 (de) 9-alpha-substituierte estratriene als selektiv wirksame estrogene
DE50306736D1 (de) Rahmen für Sessel von Sesselliften
NO20052012L (no) Indoler nyttige for behadling av androgen-reseptor relaterte sykdommer
ATE335500T1 (de) Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne
DE60321354D1 (de) Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties